ONA Therapeutics announced the appointment of Dr Haijun Sun as Chief Scientific Officer (CSO) and several appointments to its Scientific Advisory Board (SAB). The biotech company, member of CataloniaBio & HealthTech, is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer.
Dr Haijun Sun brings over 20 years of industry experience spanning broad aspects of drug discovery & development, particularly targeting therapies against tumors and the tumor microenvironment. He joins ONA from GSK where, as Head of Antibody Pharmacology, he led a team of assay biologists and immunologists advancing over twenty antibody discovery programs in oncology, inflammatory, neurological, and infectious diseases. He previously held senior leadership positions at various biotech companies in Europe and the US.
Valerie Vanhooren, Chief Executive Officer and Co-Founder of ONA Therapeutics, said: “By strengthening the team with Haijun’s extensive translational knowledge in oncology combined with an international and diverse Scientific Advisory Board, we are in a strong position as we advance to the next stage of growth.” ONA’s Scientific Advisory Board includes world-leading scientific and pharmaceutical industry experts from the US and Europe: Pamela Klein, Cédric Blanpain, Sean J. Morrison, Josep Tabernero, Mark Throsby, Salvador Aznar Benitah, ONA’s scientific co-founder.
You may also be interested in:
Comments